Research on Single-cell Sequencing of Tumor Stem cells in the Nano-Targeting of Triple-Negative Breast Cancer

Primarily attributed to its profound intratumoral heterogeneity and the lack of actionable molecular targets for therapy, triple-negative breast cancer (TNBC) exhibits the most unfavorable clinical treatment prognosis. In recent years, the emergence of single-cell sequencing (SCS) technology has provided unprecedented resolution for analyzing the internal heterogeneity of TNBC, especially showing unique advantages in analyzing the heterogeneity of tumor stem cells (CSCs). At the same time, the development of nanotechnology has provided new opportunities for targeted therapy of CSCs. Nanotargeted drugs based on the key targets identified by SCS have shown good potential in anti-resistance and anti-metastasis in preclinical studies. However, the dynamics of the tumor microenvironment, the immunogenicity of nanomaterials, and individual molecular differences remain significant challenges currently. Future research should focus on the dynamic monitoring function of SCS and the optimization of the biocompatibility of the nanomedicine delivery system to achieve the clinical translation of individualized treatment strategies.